Le Lézard
Classified in: Health
Subject: SVY

Obsessive-Compulsive Disorder Therapeutic Landscape & Pipeline Review (2020, H1)


DUBLIN, Jan. 24, 2020 /PRNewswire/ -- The "Obsessive-Compulsive Disorder - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

This report provides an overview of the Obsessive-Compulsive Disorder (Central Nervous System) pipeline landscape.

The Pharmaceutical and Healthcare latest pipeline guide

Obsessive-Compulsive Disorder - Pipeline Review, H1 2020

, provides comprehensive information on the therapeutics under development for Obsessive-Compulsive Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obsessive-Compulsive Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Obsessive-Compulsive Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Obsessive-Compulsive Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report Scope

Reasons to Buy

Key Topics Covered

  1. Introduction
  2. Report Coverage
  3. Obsessive-Compulsive Disorder - Overview
  4. Obsessive-Compulsive Disorder - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Pipeline by Universities/Institutes
  8. Products under Development by Companies
  9. Products under Development by Universities/Institutes
  10. Obsessive-Compulsive Disorder - Therapeutics Assessment
  11. Assessment by Target
  12. Assessment by Mechanism of Action
  13. Assessment by Route of Administration
  14. Assessment by Molecule Type

Featured News & Press Releases

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8d3onl

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 00:00
The nation's leader in MSK Ultrasound Injection Training, R3 Medical, announced today the course specials for the upcoming March 12th training in Las Vegas. Not only will each attendee receive a complimentary regenerative procedure, but also $500 off...

at 00:00
R3 Medical Training is now offering $500 off its upcoming two day Regenerative Aesthetics Course for those who register on the web site. The course is very hands on, including real patients, biologics and procedures. The code to use for the discount...

at 00:00
How to Deploy Root Cause & CAPA to Minimize Human Error An FDAnews Webinar Wednesday, March 4, 2020, 1:00-2:30 p.m. EST https://www.fdanews.com/minhumanerror Do employees fail because of process weaknesses that set them up for failure from the start?...

18 fév 2020
Since its inception, Paragon 28® has obsessed over every aspect of foot and ankle surgery. Committed to creating tailored solutions to improve surgical outcomes, Paragon 28® has launched innovative products and instrumentation that help streamline...

18 fév 2020
Biotech Institute, LLC, the global leader in hemp and cannabis plant breeding, science, and innovation, and Booshoot, LLC ("Booshoot") announced today that they have finalized a groundbreaking technology licensing agreement that will set a new...

18 fév 2020
UBM BN Co., Ltd., the fair manager of SECON 2020 originally scheduled for 18 - 20 March 2020 has made the decision to reschedule the event to 6 - 8 July at KINTEX, Korea.   The decision is taken after careful consideration and close consultations...



News published on 24 january 2020 at 15:30 and distributed by: